MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jmii.2010.08.003

Медицинская библиотека · Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2011

Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

Lu Ching-Lan, Lin Yu-Hui, Wong Wing-Wai, Lin Hsi-Hsin, Ho Mao-Wang, Wang Ning-Chi, Hsieh Szu-Min, Sheng Wang-Huei, Hung Chien-Ching, Chen Mao-Yuan

Клиническое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Prolonged exposure to combination antiretroviral therapy (CART) may result in hyperlipidemia and other metabolic complications. This study aimed to evaluate the clinical, virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART was switched to atazanavir-containing antiretroviral regimens.

METHODS

In this 48-week prospective, observational study that was conducted at designated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years or older who had developed hyperlipidemia after receiving CART that did not contain atazanavir were enrolled. Antiretroviral regimens were switched to regimens containing two nucleoside reverse-transcriptase inhibitors plus atazanavir 400 mg once daily or atazanavir 300 mg boosted with ritonavir 100 mg once daily. The lipid profiles, including total triglycerides, total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, CD4+ lymphocyte counts, and plasma HIV RNA load were determined every 3 months.

RESULTS

Sixty-six patients with hyperlipidemia were enrolled. At the end of the study, triglyceride levels declined by 49.0% (p = 0.0002) and total cholesterol levels by 18.1% from baseline (p < 0.0001), whereas there were no significant changes observed for low-density lipoprotein- and high-density lipoprotein-cholesterol levels. Mean CD4 lymphocyte count increased from 465 cells/μL at baseline to 498 cells/μL at the end of the study, whereas the proportion of patients with undetectable plasma HIV RNA load increased from 73.1% to 81.7%. The regimens were well tolerated.

CONCLUSIONS

Switch to atazanavir-containing regimens that were well tolerated resulted in significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and virologic responses to CART.

Для цитирования: Lu Ching-Lan, Lin Yu-Hui, Wong Wing-Wai, Lin Hsi-Hsin, Ho Mao-Wang, Wang Ning-Chi, Hsieh Szu-Min, Sheng Wang-Huei, Hung Chien-Ching, Chen Mao-Yuan. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2011. DOI: 10.1016/j.jmii.2010.08.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.